Trending...
- Purple Heart Recipient Honored by Hall of Fame Son In Viral Tribute Sparking National Conversation on Service Fatherhood, Healing and Legacy
- Lineus Medical's SafeBreak® Vascular Added to Alliant GPO Contract
- 66% of US Bankruptcies Are Medical — So Americans Are Building Businesses That Cover Healthcare Emergencies
Download
Photo courtesy of Labcorp
BURLINGTON, N.C.--(BUSINESS WIRE)--Nearly 10 million people in the United States have a history of systemic or anaphylactic reaction to insect stings, with the risk of a severe and potentially life-threatening allergic reaction. To help facilitate more effective venom therapy, Labcorp (NYSE: LH), a leading global life sciences company, has launched its unique Labcorp Clinical Decision Support (CDS) interpretative test report for its Stinging Insect Component-Specific IgE Test that provides allergen test interpretation and treatment suggestions.
More on ncarol.com
"Labcorp is the only reference laboratory to offer stinging insect (venom) component testing," said Dr. Andre Valcour, vice president and laboratory director of Labcorp Diagnostic's esoteric testing unit. "The launch of this new interpretative report is another example of how Labcorp continues to provide clinical expertise and value to providers and patients by identifying specific insect species for therapy and offering guidance on successful venom immunotherapy."
Over half of stinging insect patients test positive for allergic reactions to both honeybee and yellow jacket (wasp) venom. Labcorp's Stinging Insect Component-Specific IgE Testing helps identify the specific venom to which the patient is allergic and provides a more precise diagnosis to support venom immunotherapy. Venom-specific immunotherapy (VIT) is an effective treatment for venom allergy that can help protect against future reactions, minimize side effects and lower treatment costs.
The Labcorp CDS interpretative venom allergy report expands on prior reporting to provide report interpretation and uses current Allergy Practice Parameters, which are sponsored by the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology, to offer treatment suggestions. Dr. David Golden, a leading expert on stinging insect allergies and former chair of the Stinging Insect Hypersensitivity Practice Parameter Update workgroup, collaborated with Labcorp to establish this vital report.
"It is very important to identify the specific insect species for effective therapy," said Dr. Golden, an associate professor of medicine at Johns Hopkins University and the allergy division chief at both Sinai Hospital and Franklin Square Hospital in Baltimore, Maryland. "Venom component testing is valuable as it can differentiate between species-specific sensitization and cross-reactivity, fine tune venom diagnosis, and help physicians determine the most appropriate and cost-effective treatment plans for patients."
The Labcorp CDS interpretive report follows the Practice Parameters and provides physicians comprehensive insight on diagnostic marker interpretation, treatment suggestions and guidance for managing venom and stinging insect therapy. To learn about the Practice Parameters, visit their website.
More on ncarol.com
About Labcorp
Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With over 75,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $16 billion in FY2021. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.
Contacts
Labcorp Contacts:
Media: Christopher Allman-Bradshaw – 336-436-8263
Media@Labcorp.com
Investors: Chas Cook – 336-436-5076
Investor@Labcorp.com
0) { // Create container for hi-res image jQuery('#bw-release-hires').append('
'); }; }); ]]>
Contacts
Labcorp Contacts:
Media: Christopher Allman-Bradshaw – 336-436-8263
Media@Labcorp.com
Investors: Chas Cook – 336-436-5076
Investor@Labcorp.com
Photo courtesy of Labcorp
BURLINGTON, N.C.--(BUSINESS WIRE)--Nearly 10 million people in the United States have a history of systemic or anaphylactic reaction to insect stings, with the risk of a severe and potentially life-threatening allergic reaction. To help facilitate more effective venom therapy, Labcorp (NYSE: LH), a leading global life sciences company, has launched its unique Labcorp Clinical Decision Support (CDS) interpretative test report for its Stinging Insect Component-Specific IgE Test that provides allergen test interpretation and treatment suggestions.
More on ncarol.com
- CCHR: While Damaging Antipsychotics Win Approval, Proven Non-Drug Alternatives Remain Ignored
- Arcuri Group Announces Long‑Term Partnership with WakeMed Health & Hospitals to Deliver Situational Awareness and De‑escalation Training
- At 25, She Became One of the Youngest AAPI Female Founders to Win One of the World's Most Prestigious Design Awards for a Lamp That Makes You Smile
- Juego Studios Extends Full-Cycle Game Development & Outsourcing Capabilities to the UAE Market
- VENUS Goes Live on CATEX Exchange As UK Financial Ltd Activates The Premier Division Of The Maya Meme's League
"Labcorp is the only reference laboratory to offer stinging insect (venom) component testing," said Dr. Andre Valcour, vice president and laboratory director of Labcorp Diagnostic's esoteric testing unit. "The launch of this new interpretative report is another example of how Labcorp continues to provide clinical expertise and value to providers and patients by identifying specific insect species for therapy and offering guidance on successful venom immunotherapy."
Over half of stinging insect patients test positive for allergic reactions to both honeybee and yellow jacket (wasp) venom. Labcorp's Stinging Insect Component-Specific IgE Testing helps identify the specific venom to which the patient is allergic and provides a more precise diagnosis to support venom immunotherapy. Venom-specific immunotherapy (VIT) is an effective treatment for venom allergy that can help protect against future reactions, minimize side effects and lower treatment costs.
The Labcorp CDS interpretative venom allergy report expands on prior reporting to provide report interpretation and uses current Allergy Practice Parameters, which are sponsored by the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology, to offer treatment suggestions. Dr. David Golden, a leading expert on stinging insect allergies and former chair of the Stinging Insect Hypersensitivity Practice Parameter Update workgroup, collaborated with Labcorp to establish this vital report.
"It is very important to identify the specific insect species for effective therapy," said Dr. Golden, an associate professor of medicine at Johns Hopkins University and the allergy division chief at both Sinai Hospital and Franklin Square Hospital in Baltimore, Maryland. "Venom component testing is valuable as it can differentiate between species-specific sensitization and cross-reactivity, fine tune venom diagnosis, and help physicians determine the most appropriate and cost-effective treatment plans for patients."
The Labcorp CDS interpretive report follows the Practice Parameters and provides physicians comprehensive insight on diagnostic marker interpretation, treatment suggestions and guidance for managing venom and stinging insect therapy. To learn about the Practice Parameters, visit their website.
More on ncarol.com
- Atlanta Tech Founder Seeks Clarity on Intellectual Property and Innovation Policy
- FPTower Inc. nonprofit launches coastal safety raffle fundraiser
- Purple Heart Recipient Honored by Hall of Fame Son In Viral Tribute Sparking National Conversation on Service Fatherhood, Healing and Legacy
- STEM Agent Academy Mission 01: Reclaiming Children's Curiosity from the Digital Void
- Amicly Launches as a Safety-First Social App Designed to Help People Build Real, Meaningful Friendships
About Labcorp
Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With over 75,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $16 billion in FY2021. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.
Contacts
Labcorp Contacts:
Media: Christopher Allman-Bradshaw – 336-436-8263
Media@Labcorp.com
Investors: Chas Cook – 336-436-5076
Investor@Labcorp.com
0) { // Create container for hi-res image jQuery('#bw-release-hires').append('
'); }; }); ]]>
Contacts
Labcorp Contacts:
Media: Christopher Allman-Bradshaw – 336-436-8263
Media@Labcorp.com
Investors: Chas Cook – 336-436-5076
Investor@Labcorp.com
Filed Under: Business
0 Comments
Latest on ncarol.com
- ASTI Ignites the Space Economy: Powering SpaceX's NOVI AI Pathfinder with Breakthrough Solar Technology: Ascent Solar Technologies (N A S D A Q: ASTI)
- STEM For Kids Launches Root Protocol™: A Human Bridge for Gen Alpha's Digital Curiosity Crisis
- Hiring has reached a "Digital Stalemate"—Now, an ex-Google recruiter is giving candidates the answers
- 2026 Pre-Season Testing Confirms a Two-Tier Grid as Energy Management Defines Formula 1's New Era
- Platinum Car Audio LLC Focuses on Customer-Driven Vehicle Audio and Electronics Solutions
- Postmortem Pathology Expands Independent Autopsy Services in Kansas City
- Postmortem Pathology Expands Independent Autopsy Services Across Colorado
- $38 Million in U.S. Government Contract Awards Secured Through Strategic Partner. Establishing Multi-Year Defense Revenue Platform Through 2032: $BLIS
- Mecpow M1: A Safe & Affordable Laser Engraver Built for Home DIY Beginners
- CrashStory.com Launches First Colorado Crash Data Platform Built for Victims, Not Lawyers
- Inkdnylon Earns BBB Accreditation for Verified Business Integrity
- Josh Stout "The Western Project"
- Open House Momentum Builds at Heritage at South Brunswick
- A Celebration of Visibility, Voice and Excellence: The 57th NAACP Image Awards Golf Invitational, Presented by Wells Fargo, A PGD Global Production
- Athens in Spring: A Culinary City Break That Rivals Paris and Copenhagen
- ClearSight Therapeutics Signs LOI with Covalent Medical for $60M Multi-Channel OTC Eye Care Partnership
- Jayne Williams Joins Century Fasteners Corp. Sales and Business Development Team
- Rocket Fibre Services Growing Customer Base With netElastic Networking Software
- Cummings Graduate Institute for Behavioral Health Studies Honors New Doctor of Behavioral Health Graduates
- IDpack v4 Launches: A Major Evolution in Cloud-Based ID Card Issuance